Company intelligence / Profile preview
4B Technologies
Beijing, Beijing, China
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
The company has completed patient enrollment for a clinical trial of an AI-discovered ALS drug supported by Insilico Medicine. They also have a food effect study for FB-1071 in healthy Chinese adult subjects that started in April 2023.
- Therapeutic areas
- OphthalmologyNeurology
- Modalities
- Monoclonal antibodyAntibodySmall molecule drug
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Insilico Medicine
Beyond the preview
Go deeper on 4B Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4B Technologies.